Clinical Outcomes and Risk Factors of Rebleeding Following Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Hemorrhage

Ki Tae Suk¹, Hyun-Soo Kim², Chang Seob Lee¹, Il Young Lee², Moon Young Kim², Jae Woo Kim², Soon Koo Baik², Sang Ok Kwon³, Dong Ki Lee⁴ and Young Lim Ham⁵

¹Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, ²Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, ³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, ⁴Department of Emergency Medical Technology, Daewon University College, Jecheon, Korea

Background/Aims: Rebleeding after endoscopic therapy for non-variceal upper gastrointestinal hemorrhage (NGIH) is the most important predictive factor of mortality. We evaluated the risk factors of rebleeding in patients undergoing endoscopic therapy for the NGIH.

Methods: Between January 2003 and January 2007, 554 bleeding events in 487 patients who underwent endoscopic therapy for NGIH were retrospectively enrolled. We reviewed the clinicoeoscopy characteristics of patients with rebleeding and compared them with those of patients without rebleeding.

Results: The incidence of rebleeding was 21.7% (n=120). In the multivariate analysis, initial hemoglobin level ≤9 g/dL (p=0.002; odds ratio [OR], 2.433), inexperienced endoscopist with less than 2 years of experience in therapeutic endoscopy (p=0.001; OR, 2.418), the need for more 15 cc of epinephrine (p=0.001; OR, 2.570), injection therapy compared to thermal and injection therapy (p=0.001; OR, 2.840), and comorbidity with chronic renal disease (p=0.004; OR, 2.908) or liver cirrhosis (p=0.010; OR, 2.870) were risk factors for rebleeding following endoscopic therapy.

Conclusions: Together with patients with low hemoglobin level at presentation, chronic renal disease, liver cirrhosis, the need for more 15 cc of epinephrine, or therapy done by inexperienced endoscopist were risk factors for the development of rebleeding.

Key Words: Gastrointestinal hemorrhage; Risk factors; Endoscopy; Therapy

INTRODUCTION

Endoscopic therapies such as injections, clipping, and thermal ablation have been effective in achieving primary hemostasis in patients with non-variceal upper gastrointestinal hemorrhage (NGIH).¹ Despite these advancements in therapeutic endoscopy, rebleeding recurs in 15-20% of cases after successful endoscopic therapy for NGIH.² Moreover, NGIH remains a common cause of hospitalization and rebleeding, which are the most important predictive factors of mortality, occurring in 3.1-7.0% of patients.³⁻⁵ Therefore, prevention and prediction of patients at risk of rebleeding, after initial endoscopic therapy, is essential for a successful outcome in patients with NGIH.

The presence of large ulcers (≥1 cm) with severe bleeding at presentation is well known to be predictive of rebleeding.⁶⁻⁸ Proton pump inhibitor (PPI) has been reported as an effective medication for recurrent bleeding after endoscopic therapy.⁷⁻⁸ In addition, advanced age, comorbidity, shock, rebleeding, and the need for surgery have been associated with an increase in mortality after endoscopic hemostasis.⁹⁻¹⁰ However, little is known about additional risk factors for rebleeding after endoscopic therapy, although scoring systems have been developed for the prediction of outcomes in patients with NGIH.¹¹ Therefore, identification of the factors related to the development of rebleeding, after endoscopic therapy for NGIH, might improve patient management and outcome. The aim of this study was to evalu-
ate the clinical outcome and potential predictive factors associated with rebleeding in patients undergoing endoscopic therapy for NGIH.

**MATERIALS AND METHODS**

**Patients**

Between January 2003 and January 2007, a total of 554 bleeding events in 487 patients (M:F=366:121; Age, 58.9±15.3) who underwent endoscopic therapy for NGIH were retrospectively enrolled. Patients that were not treated with endoscopic therapy or had Mallory-Weiss syndrome were excluded. The clinical and endoscopic characteristics of patients with rebleeding were reviewed and compared with patients who did not develop rebleeding. Patient characteristics and rebleeding related data were recorded for the following variables: gender, age, alcohol and smoking history, underlying disease (chronic renal failure, liver cirrhosis, hypertension without aspirin use, diabetes mellitus, aspirin or clopidogrel use, current use of coumadin, and others), past gastrointestinal bleeding history, endoscopic findings (cause and location of bleeding, size, and bleeding state), endoscopic therapies, endoscopists’ experiences, clinical outcomes, and mortality. A written informed consent for therapy was obtained from each patient. The study was carried out in accordance with the Helsinki Declaration after the approval of Institutional Review Board of Wonju Christian Hospital.

All patients were managed according to NIGH treatment protocol of the hospital. The patients’ vital signs were assessed at 10 minutes interval before the endoscopy, and then every 2 hours for 24 hours after the endoscopy, and every 6 hours thereafter until the follow-up after the endoscopy. The hemoglobin level was checked at least once daily; a blood transfusion was given if the hemoglobin level decreased to lower than 9 g/dL. Rebleeding was defined by at least two of the followings: new-onset hematemesis or melena with blood pressure <100 mm Hg, decrease of more than 2 g/dL in hemoglobin level, endoscopic confirmation of bleeding, or pathologic lesion which required endoscopic therapy within 7 days after the initial therapy. Bleeding state was classified by Forrest classification (Fig. 1): active spurting bleeding (Ia), active oozing bleeding (Ib), vessel exposure (IIa), and red or black adherent clots (IIb).

**Endoscopic therapy**

All feasible patients presented to the hospital with NGIH underwent endoscopy within 24 hours. The patients received intravenous PPIs to promote healing of the lesion before and af-

---

**Fig. 1.** Bleeding status. (A) Active pumping. (B) Active oozing. (C) Vessel exposure. (D) Red or black clot.
ter the endoscopic therapy. Levin tube insertion and irrigation with more than 3,000 cc of normal saline was provided before the initial endoscopy. Thirteen gastroenterologists, with more than 2 years of experience (>6,000 cases of endoscopy) of performing endoscopy, carried out the therapeutic endoscopy for NGIH during the study period. Therapies used for the initial NGIH were 1:10,000 epinephrine injection, GLUE (thrombin/fibrin, Greenplast; Green Cross, Yongin, Korea) injection, hemoclipping, and thermal ablation (monopolar or argon plasma coagulation [APC]). Patients were scheduled to have a follow-up endoscopy within 24 hours. If the general condition was not suitable for an endoscopy, the follow-up endoscopy was delayed. After evaluation of the follow-up endoscopy, further management was decided including: the appropriate meal time, follow-up endoscopic therapy, endoscopic biopsy, and Helicobacter pylori test. If active bleeding or vessel exposure was observed at the follow-up endoscopy, it was considered as a rebleeding and a second session of endoscopic therapy was planned (Fig. 2). If the bleeding continued after the endoscopic therapy, surgery or embolization therapy was performed. During fasting periods, 40 mg of intravenous pantoprazole sodium was injected, as a bolus, every 12 hours. And then, all patients were treated with oral PPI at a standard dose every morning during the next 6-8 weeks. Patients with positive rapid urea test results were provided with 7-day eradication therapy (10 mg or 20 mg of PPI+1 g of amoxicillin+500 mg of clarithromycin, b.i.d.).

Patients underwent blood test, abdominal ultrasound, and a routine abdominal X-ray during the admission and on an outpatient basis after the procedure to assess bleeding, perforation, or other possible complications.

**Statistical analysis**

An independent-samples t-test was used for comparison of continuous variables. Data were expressed as means and standard deviations. The correlation between rebleeding and risk variables was assessed by univariate analysis. In addition, multivariate logistic regression analysis was performed to identify factors related to rebleeding and mortality. Age, gender, and plausible risk factors (p<0.25) from the results of the univariate analysis were used in the multivariate analysis where appropriate. The enter method was performed to find the odds ratios; and the relationship of each variable in the multivariate analysis was analyzed. Data were analyzed with statistical software (SPSS version 13.0; SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered significant in all tests.

**RESULTS**

**Patient characteristics and clinical outcomes of rebleeding**

The mean age of the patients was 59.1 years (range, 13-93 years). Among a total of 554 patients, 120 (21.7%) patients were
diagnosed as rebleeding after the endoscopic therapy. The causes of NGIH were gastric ulcer in 327 (59.1%), duodenal ulcer in 173 (31.2%), Dieulafoy lesion in 26 (4.7%), marginal ulcer in 16 (2.9%), and cancer bleeding in 12 (2.2%) patients. Comorbid diseases and medications used included chronic renal failure in 70 (12.6%), aspirin or clopidogrel use in 68 (12.3%), liver cirrhosis in 61 (11.0%), hypertension without aspirin therapy in 50 (9.0%), diabetes mellitus in 25 (4.5%), diabetes mellitus and hypertension without aspirin therapy in 17 (3.1%), and others in 8 (1.4%) patients. The remaining (229 patients) had no underlying disease. The average hospital stay was 12 days (range, 1-210 days) after the endoscopic therapy. Twenty patients (3.6%) underwent surgery and 1 patient was treated with embolization because of continuous bleeding after therapy. Forty-four patients (7.9%) died after the endoscopic therapy (Table 1).

With regard to endoscopic characteristics (Table 2), the bleeding was characterized by vessel exposure in 257 (46.4%), active ooze in 179 (32.3%), active spurting bleeding in 48 (8.7%), and red and black clots in 70 (12.6%) patients. APC therapy (18.6%) was most commonly used as a single therapy. The mean amount of epinephrine used in therapy was 13.5 (12.8) cc. In the combination therapy, epinephrine and GLUE (Greenplast) injection therapy (22.4%) was the most common combination therapy in this study. The mean ulcer size was 13.6 (10.2) mm. The mean therapeutic experience of the endoscopist was 3.7 (3.0) years. In the gastric lesions, most common locations of bleeding were the body and lesser curvature.

### Table 1. Clinical Characteristics of Patients

| Characteristic                        | Rebleeding (n=120) | No rebleeding (n=434) | p-value |
|---------------------------------------|--------------------|-----------------------|---------|
| Gender, male/female                   | 98/22              | 329/105               | 0.219   |
| Age, yr                               | 59.4±13.3          | 59.1±15.6             | 0.842   |
| Alcohol history, yes/no               | 74/46              | 237/196               | 0.212   |
| Smoking history, yes/no               | 67/53              | 229/204               | 0.135   |
| Previous bleeding history, times      | 1.1±0.3            | 1.1±0.4               | 0.771   |
| Initial SBP , mm Hg                   | 115±29             | 117±26                | 0.520   |
| Initial DBP, mm Hg                    | 72±16              | 72±15                 | 0.676   |
| Initial heart rate/min                | 94±18              | 91±19                 | 0.091   |
| Laboratory findings                   |                    |                       |         |
| Hemoglobin, g/dL                      | 8.5±2.5            | 9.2±2.8               | 0.010   |
| Platelet, 10⁹/L                       | 209±150            | 241±112               | 0.009   |
| INR                                   | 1.2±0.4            | 1.2±1.0               | 0.597   |
| Comorbid diseases                      |                    |                       | 0.000   |
| No specific disease or medication     | 53 (44)            | 277 (64)              |         |
| Chronic renal failure                 | 27 (23)            | 43 (10)               |         |
| Liver cirrhosis                       | 18 (15)            | 43 (10)               |         |
| Coumadin use                          | 7 (6)              | 18 (4)                |         |
| Aspirin or clopidogrel use            | 15 (13)            | 53 (12)               |         |
| Meal day after endoscopic therapy     | 5.5±6.2            | 2.2±3.5               | 0.000   |
| Admission days after endoscopic therapy | 17.6±15.5          | 10.5±18.4             | 0.000   |
| Survival                              | 96 (80)            | 415 (96)              | 0.000   |

Values are presented as mean±SD or number (%); p-value for Pearson’s χ² test (2 by 2 and 2 by x) and the independent-samples t-test for comparison of continuous variables.

SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; INR, international normalized ratio.

### Factors related to rebleeding

The univariate analysis showed no significant differences in gender, age, alcohol and smoking history, previous bleeding history, international normalized ratio, cause of bleeding, size of ulcer, and the number of biopsy in the rebleeding group compared to the group without rebleeding. However, lower initial hemoglobin level and platelet count (p=0.010 and p=0.009), comorbidity with chronic renal disease (p=0.000), degree of initial bleeding state (p=0.010), endoscopic treatment modality (p=0.002), experience of the endoscopist (p=0.002), and the need for large amount (>15 cc) of epinephrine during the therapy (p=0.000), were found to be positively related to rebleeding (Tables 1, 2).

In the multivariate analysis, initial hemoglobin level ≤9 g/dL (p=0.002; odds ratio [OR], 2.433), unskillful endoscopist with...
less than 2 years of therapeutic endoscopy experience (p=0.001; OR, 2.418), the need for more 15 cc of epinephrine (p=0.001; OR, 2.570), injection therapy compared to thermal and injection therapy (p=0.001; OR, 2.840), and comorbidity with chronic renal disease (p=0.004; OR, 2.908) or liver cirrhosis (p=0.010; OR, 2.870) were risk factors of rebleeding following endoscopic therapy. Initial active spurting bleeding (p=0.021; OR, 5.208) and rebleeding (p=0.000; OR, 6.391) were significantly related to mortality (Table 3).

Factors related to mortality
The mortality rate of patients without comorbid disease (7.0%, n=23) was lower than that of patients with chronic renal disease (17.1%, n=12) or liver cirrhosis (11.5%, n=7). In the univariate analysis, the mortality rate was significantly higher in patients with advanced age, history of alcohol consumption, location of bleeding in the body, the presence of rebleeding or surgery, the need for large amounts of epinephrine, low blood pressure or platelet count at presentation, fast heart rate on presentation, active bleeding, and a longer hospitalization (p<0.05).

The multivariate analysis showed that initial active spurting bleeding (p=0.021; OR, 5.208) and rebleeding (p=0.000; OR, 6.391) were significantly related to the mortality following the endoscopic therapy (Table 4).

DISCUSSION
In this study, the frequency of rebleeding after the initial endoscopic therapy was 22.1%, which is similar to prior reports. With regard to PPI use, prior studies suggested that PPI administration reduced the rebleeding rate to 4%; a rate lower than the finding of this study. The definition of rebleeding period

---

**Table 2.** Endoscopic Characteristics of Patients

| Variable                              | Rebleeding (n=120) | No rebleeding (n=434) | p-value |
|---------------------------------------|--------------------|-----------------------|---------|
| Causes of bleeding                    |                    |                       | 0.493   |
| Gastric ulcer                        | 72 (59)            | 255 (59)              |         |
| Duodenal ulcer                       | 40 (33)            | 133 (31)              |         |
| Dieulafoy lesion                     | 2 (2)              | 24 (20)               |         |
| Anastomosis site after operation     | 3 (3)              | 13 (11)               |         |
| Cancer bleeding                      | 3 (3)              | 9 (8)                 |         |
| Bleeding state                       |                    |                       | 0.010   |
| Active spurting bleeding             | 18 (15)            | 30 (7)                |         |
| Active oozing bleeding               | 47 (39)            | 132 (30)              |         |
| Vessel exposure                      | 42 (35)            | 215 (50)              |         |
| Clot                                 | 13 (11)            | 57 (13)               |         |
| Size of ulcer, mm<sup>b</sup>        | 14.6±10.1          | 13.3±10.3             | 0.235   |
| Therapy                              |                    |                       | 0.002   |
| Injection                            | 63 (52)            | 145 (33)              |         |
| Thermal ablation<sup>b</sup>         | 16 (13)            | 71 (16)               |         |
| Clip                                 | 6 (5)              | 32 (7)                |         |
| Injection and thermal ablation       | 24 (20)            | 148 (34)              |         |
| Injection and clip                   | 7 (6)              | 31 (7)                |         |
| Injection and thermal ablation and clip | 4 (3)              | 6 (1)                |         |
| Band ligation                        | 0 (0)              | 1 (0)                 |         |
| Experience of endoscopic therapy     |                    |                       | 0.002   |
| ≤2 yr                                | 73 (61)            | 193 (80)              |         |
| >2 yr                                | 47 (39)            | 241 (20)              |         |
| Amount of epinephrine used           |                    |                       | 0.000   |
| ≤15 cc                               | 30 (32)            | 167 (52)              |         |
| >15 cc                               | 65 (68)            | 154 (48)              |         |

Values are presented as mean±SD or number (%). p-value for Pearson’s χ<sup>2</sup> test (2 by x) and the independent-samples t-test for comparison of continuous variables.

<sup>a</sup>Argon plasma coagulation or electrocoagulation.

---

KT Suk et al.
(<7 days), selection of enrolled patients who received endoscopic hemostasis, and administration method of PPI might have affected the results of this study, because most prior studies used continuous infusion of high dose PPI with or without bolus injection. Also, several of these studies included patients whose ulcers did not require an endoscopic therapy or rebleeding lasted

Table 3. Multivariate Analysis of Factors for the Risk of Rebleeding

| Variable                                      | p-value | OR (95% CI)     |
|-----------------------------------------------|---------|-----------------|
| Age                                           | 0.516   | 1.006 (0.988-1.024) |
| Gender (female/male<sup>a</sup>)              | 0.143   | 0.612 (0.317-1.181) |
| Bleeding state                                |         |                 |
| Active spurting bleeding<sup>a</sup>          |         |                 |
| Active oozing bleeding                        | 0.543   | 0.772 (0.335-1.777) |
| Vessel exposure                               | 0.128   | 0.523 (0.228-1.204) |
| Clots                                         | 0.053   | 0.344 (0.117-1.016) |
| Endoscopic therapy                            |         |                 |
| Injection<sup>a</sup>                         |         |                 |
| Thermal ablation<sup>b</sup>                  | 0.613   | 2.589 (0.065-102.921) |
| Clip                                          | 0.116   | 0.279 (0.057-1.371) |
| Injection+thermal ablation                    | 0.001   | 0.352 (0.193-0.640) |
| Injection+clip                                | 0.062   | 0.374 (0.133-1.051) |
| Injection+thermal ablation+clip               | 0.275   | 2.813 (0.440-17.988) |
| Comorbid diseases                              |         |                 |
| No specific disease or medication<sup>a</sup> |         |                 |
| Chronic renal failure                         | 0.004   | 2.908 (1.393-6.068) |
| Liver cirrhosis                               | 0.010   | 2.870 (1.289-6.387) |
| Coumadin use                                  | 0.495   | 1.563 (0.433-5.643) |
| Aspirin or clopidogrel use                    | 0.353   | 1.501 (0.637-3.337) |
| Hemoglobin (≤9/>9 g/dL<sup>a</sup>)            | 0.002   | 2.433 (1.376-4.305) |
| Experience of endoscopist (≤2/>2 yr<sup>a</sup>) | 0.001   | 2.418 (1.402-4.144) |
| Amount of epinephrine used (>15/≤15 cc<sup>a</sup>) | 0.001   | 2.570 (1.492-4.426) |

OR, odds ratio; CI, confidence interval.
<sup>a</sup>Reference category; <sup>b</sup>Argon plasma coagulation or electrocoagulation.

Table 4. Multivariate Analysis of Factors for the Risk of Mortality

| Variable                                      | p-value | OR (95% CI)     |
|-----------------------------------------------|---------|-----------------|
| Age                                           | 0.212   | 1.091 (0.990-1.049) |
| Gender (female/male<sup>a</sup>)              | 0.410   | 0.651 (0.235-1.805) |
| Alcohol (yes/no<sup>a</sup>)                  | 0.094   | 0.468 (0.192-1.138) |
| Amount of used epinephrine (>15/≤15 cc<sup>a</sup>) | 0.160   | 1.896 (0.777-4.625) |
| Operation                                     | 0.921   | 0.740 (0.173-3.167) |
| Bleeding state                                |         |                 |
| Active spurting bleeding<sup>a</sup>          |         |                 |
| Active oozing bleeding                        | 0.812   | 0.868 (0.270-2.789) |
| Vessel exposure                               | 0.021   | 0.192 (0.047-0.779) |
| Clots                                         | 0.155   | 0.269 (0.044-1.643) |
| Rebleeding (yes/no<sup>a</sup>)               | 0.000   | 6.391 (2.748-14.864) |

OR, odds ratio; CI, confidence interval.
<sup>a</sup>Reference category.
for a short period (<3 days).\textsuperscript{13-16} Treatment with continuous PPI infusion is thought to be associated with a better outcome by improving wound healing. However, prospective studies with gastric pH measurements during various administration methods of PPI are needed to further explain the underlying mechanism of better hemostasis.

Rebleeding after endoscopic hemostasis is associated with an increased risk of mortality, prolonged hospital stay, and increased medical expenses.\textsuperscript{3,9} In this study, endoscopic findings of active spurting bleeding and the presence of rebleeding was associated with poor prognosis. Chiu et al.\textsuperscript{4} reported that larger ulcers with stigmata and high American Society of Anesthesiologists (ASA) general score (grade III and IV) were important predictors of recurrent bleeding after a second endoscopy. However, we did not check the ASA general score in this study and the relation between ulcer size and rebleeding was not confirmed.

Comorbid disease with chronic renal failure and liver cirrhosis were major risk factors for rebleeding in this study. A recent study demonstrated that dialysis patients with end stage renal disease were more likely to experience rebleeding than patients who were not on dialysis after ulcer bleeding.\textsuperscript{17} Little has been known about the underlying mechanisms for high risks of bleeding, rebleeding, and mortality in patients with chronic renal failure. However, decreased bicarbonate secretion, abnormal coagulation system, or uremic platelet dysfunction could be related to high risk of rebleeding.\textsuperscript{17,18} Rebleeding also might be common in these patients, since most patients with renal disease and cirrhosis show advanced ASA status.\textsuperscript{19} In this study, 39% and 30% of patients with chronic renal failure and liver cirrhosis, respectively, experienced rebleeding after the first endoscopic treatment. A careful follow up with intensive monitoring is indicated, therefore, in these patients after the endoscopic therapy.

Other factors such as coumadin, aspirin, or clopidogrel use were not related to rebleeding. These findings are consistent with a recent report showing that anticoagulation use did not increase the risk of rebleeding.\textsuperscript{10} The suppression of gastroduodenal mucosal prostaglandin synthesis is associated with the mucosal damage caused by aspirin.\textsuperscript{20} Peters et al.\textsuperscript{21} suggested that the risk of bleeding increases with aspirin dose increase with or without clopidogrel. However, these studies did not report on the association between rebleeding and anticoagulation therapy. In this present study, anticoagulation therapy was not related to rebleeding which was similar to other prior reports.\textsuperscript{4} Immediate cessation of medication after the suspicion of bleeding might be associated with the negative correlation.

Considering of procedure-related factors may be important to reduce the mortality risk due to bleeding during and/or after endoscopic therapy. At the time of therapy, inexperienced endoscopists and the need for large amounts of epinephrine were also definite risk factors for rebleeding in the current study. We found that 61% (73/120) of the patients with rebleeding had endoscopic therapy by an endoscopist with less than 2 years of therapeutic endoscopy experience. In addition, 30% (219) of bleeding cases, which could not be controlled by ≤15 cc of epinephrine injections, rebled within 7 days of the initial endoscopy in this study. These findings were unique in the current study. Therefore, more careful approaches under the expert supervision, short term follow-up endoscopy, and close and intensive monitoring are needed for patients who underwent endoscopic therapy in circumstances with these 2 risk conditions.

In the consensus recommendations for managing patients with NGIH, combination therapy was superior to single therapy.\textsuperscript{1,12} Thermal ablation such as APC or electrocoagulation with injection therapy significantly reduced rebleeding in this study (\(p<0.01\)), suggesting the intensive therapy using combination method by an expert is a primary determinant of better outcome in patients with NGIH.

Low hemoglobin level and active pumping bleeding at presentation were other risk factors of rebleeding. Active pumping means that seeding vessel is relatively large; and low hemoglobin level might be a result of massive arterial bleeding. As a result, these findings suggest that massive bleeding from a relatively large vessel was positively related to rebleeding after endoscopic therapy and consequent poor outcomes.

The limitations of this study include the retrospective study design and the use of different PPI doses and administration methods. Therefore, prospective studies using the same PPI administration are needed to properly identify the risk predictors for rebleeding in a larger number of patients. Currently, a lot of comparative studies reported the advantages of different PPIs, doses, treatment methods, therapy protocols, scoring systems, and costs. Therefore, new treatments for reducing rebleeding should be verified over time.

In conclusion, the results of this study showed that low hemoglobin level at presentation, chronic renal disease, liver cirrhosis, treatment with endoscopic injection therapy (>15 cc of epinephrine) or by inexperienced endoscopist were significantly related to the development of rebleeding after the endoscopic therapy. Moreover, since rebleeding is one of the risk factors of mortality, close follow up with intensive monitoring is indicated in these patients after endoscopic therapy.

Conflicts of Interest
The authors have no financial conflicts of interest.

Acknowledgments
This research was supported by Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (20110006074).
REFERENCES

1. Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-857.

2. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;331:717-727.

3. Miller T, Barkun AN, Martel M. Non-variceal upper GI bleeding in patients already hospitalized for another condition. Am J Gastroenterol 2009;104:330-339.

4. Chiu PW, Joeng HK, Choi CL, Kwong KH, Ng EK, Lam SH. Predictors of peptic ulcer rebleeding after scheduled second endoscopy: clinical or endoscopic factors? Endoscopy 2006;38:726-729.

5. Lin HI, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998;158:54-58.

6. Wong SK, Yu LM, Lau JY, et al. Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer. Gut 2002;50:322-325.

7. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003;17:211-216.

8. Chan FK, Chang JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-244.

9. Chiu PW, Ng EK, Cheung FK, et al. Predicting mortality in patients with bleeding peptic ulcers after therapeutic endoscopy. Clin Gastroenterol Hepatol 2009;7:311-316.

10. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007;102:290-296.

11. Tajima A, Koizumi K, Suzuki K, et al. Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol 2008;23 Suppl 2:S237-S241.

12. Andriulli A, Annese V, Caruso N, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol 2005;100:207-219.

13. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-316.

14. Ng FH, Wong SY, Lam KE, et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008;103:865-871.

15. Marmo R, Koch M, Cipolletta L, et al. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study. Am J Gastroenterol 2008;103:1639-1647.

16. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009;150:455-464.

17. Cheung I, Yu A, LaBossiere J, Zhu Q, Fedorak RN. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc 2010;71:44-49.

18. Dinoso VP Jr, Murthy SN, Saris AL, et al. Gastric and pancreatic function in patients with end-stage renal disease. J Clin Gastroenterol 1982;4:321-324.

19. Hu ML, Wu KL, Chiu KW, et al. Predictors of rebleeding after initial hemostasis with epinephrine injection in high-risk ulcers. World J Gastroenterol 2010;16:5490-5495.

20. Vallurupalli NG, Goldhaber SZ. Gastrointestinal complications of dual antiplatelet therapy. Circulation 2006;113:e655-e658.

21. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687.

22. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-113.